CellCure Neurosciences Overview
Cell Cure Neurosciences is a biotechnology company developing cell therapies based on the use of human embryonic stem cells for the treatment of retinal and neural degenerative diseases. The company uses these powerful stem cells to manufacture the retinal pigment epithelial (RPE) cell. Cell Cure’s first product in development, OpRegen, contains hESC-derived RPE cells to treat age-related macular degeneration (AMD). OpRegen is being developed as a frontline therapy for the dry form of AMD, which affects approximately 90% of AMD patients. Cell Cure is currently conducting a phase 1/2 clinical trial of OpRegen to treat the larger market of dry AMD, for which there is currently no FDA-approved therapeutic. The company has recently completed construction of a cGMP manufacturing facility for the production of OpRegen and other cell therapy products. Cell Cure Neurosciences is a fully owned subsidiary of California-based Lineage Cell Therapeutics, formerly BioTime.
Cumulative Funding Raised Over Time ($)
$3.5MNov 2012
$4.5MOct 2009
$11.6MOct 2010
Latest News
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
growth-positive
Hadasit sells stem cell co Cell Cure stake
Hadasit Bio-Holdings has sold its 21% stake in Cell Cure to BioTime for $12.75 million. The deal reflects a $60 million value for Cell Cure, a stem cell company developing treatments for retinal degeneration. Hadasit believes it will post a $9 million pre-tax accounting profit following the deal. BioTime already owns 62% of Cell Cure and will have full ownership after the deal. BioTime has given Hadasit a five-year option to buy back 5% of Cell Cure. The announcement caused Hadasits share price to jump 35%.
Investment
growth-positive
US co BioTime dual-listing on TASE
US biotechnology company, BioTime, Inc., is set to dual list on the Tel Aviv Stock Exchange. The company, which has a market cap of $268 million, will be traded under the ticker symbol BTX. BioTime CEO, Michael West, believes that the dual listing will help the company to open a new access point for their shares in the Israeli market and expand and diversify their shareholder base. The company has two Israeli subsidiaries, Cell Cure Neurosciences Ltd. and LifeMap Sciences Ltd.
Public TradingExpand
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $21.79M |
| Last funding | $2.5M |
| Stage | Seed |
| Rounds | 9 |
| Investors | 3 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | lineagecell.com/manufacturing/ |
| Careers | Careers page |
Locations
Hadassah Ein Kerem, Jerusalem, Israel
Photos & Videos
No files yet
CellCure Neurosciences Business
Business models
B2C
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsHealthcareCore Technology
BiologicalsCellsTags (10)
regenerative-medicinedegenerative-diseasesneurologycell-therapyeye-diseasesstem-cellsbiotechnologyophthalmologymedical-technologiestreatmentsGeographic Markets
United StatesCellCure Neurosciences Financials
$21.79M
Total funding
Undisclosed
Capital raised
$2.5M
Last funding
Seed
Funding stage
9
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$3.5MNov 2012
$4.5MOct 2009
$11.6MOct 2010
Private Equity Funding
Undisclosed Round
Nov 2012
$3.5M
BioTime Inc.
Undisclosed Round
Oct 2010
$7.1M
BioTime Inc., Hadasit Bio-Holdings, Teva Pharmaceuticals
Convertible Debt
Oct 2009
$1M
Hadasit Bio-Holdings
Non-Equity Funding
GrantEvent
May 2019
$2.5M
Israel Innovation Authority
GrantEvent
Jun 2016
$2.2M
Israel Innovation Authority
GrantEvent
May 2015
$1.6M
GrantEvent
Dec 2013
$1.74M
Office of the Chief Scientist
GrantEvent
May 2013
$1.5M
Office of the Chief Scientist
GrantEvent
Jan 2009
$650K
The Michael J. Fox Foundation for Parkinson's Research
CellCure Neurosciences Lifecycle
Cumulative Funding Raised Over Time
$3.5MNov 2012
$4.5MOct 2009
$11.6MOct 2010
All Events
Undisclosed Round
Nov 2012
$3.5M
BioTime Inc.
Undisclosed Round
Oct 2010
$7.1M
BioTime Inc., Hadasit Bio-Holdings, Teva Pharmaceuticals
Convertible Debt
Oct 2009
$1M
Hadasit Bio-Holdings
GrantEvent
May 2019
$2.5M
Israel Innovation Authority
GrantEvent
Jun 2016
$2.2M
Israel Innovation Authority
GrantEvent
May 2015
$1.6M
GrantEvent
Dec 2013
$1.74M
Office of the Chief Scientist
GrantEvent
May 2013
$1.5M
Office of the Chief Scientist
GrantEvent
Jan 2009
$650K
The Michael J. Fox Foundation for Parkinson's Research
CellCure Neurosciences News
7 articlesLineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
growth-positive
Hadasit sells stem cell co Cell Cure stake
Hadasit Bio-Holdings has sold its 21% stake in Cell Cure to BioTime for $12.75 million. The deal reflects a $60 million value for Cell Cure, a stem cell company developing treatments for retinal degeneration. Hadasit believes it will post a $9 million pre-tax accounting profit following the deal. BioTime already owns 62% of Cell Cure and will have full ownership after the deal. BioTime has given Hadasit a five-year option to buy back 5% of Cell Cure. The announcement caused Hadasits share price to jump 35%.
Investment
growth-positive
US co BioTime dual-listing on TASE
US biotechnology company, BioTime, Inc., is set to dual list on the Tel Aviv Stock Exchange. The company, which has a market cap of $268 million, will be traded under the ticker symbol BTX. BioTime CEO, Michael West, believes that the dual listing will help the company to open a new access point for their shares in the Israeli market and expand and diversify their shareholder base. The company has two Israeli subsidiaries, Cell Cure Neurosciences Ltd. and LifeMap Sciences Ltd.
Public TradingExpand
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
growth-positive
Cell Cure Neurosciences awarded $1.5m Chief Scientist grant
Stem cell company Cell Cure Neurosciences has been awarded a NIS 5.34 million grant for the development of OpRegen, a cell-based therapeutic product for the treatment of age-related macular degeneration. The company plans to complete preclinical testing and file an application for human clinical trials in 2014. Cell Cure is developing therapeutic cells for the treatment of retinal and neural degenerative disease. The company was acquired by BioTime in 2010 and has received investments from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio Holdings Ltd.
Investment
growth-positive
Stem cell co CellCure raises $7.1m
CellCure Neurosciences Ltd., a stem cell company, has raised $7.1 million in a funding round. Teva Pharmaceutical Industries Ltd., BioTime Inc., and Hadasit Bio Holdings Ltd. are among the investors. Teva will receive rights to CellCures AMD eye disease treatment and will invest $2 million immediately. BioTime is the biggest investor in the round, contributing $4.1 million. Hadasit also invested $1 million and converted its previous loan into equity. This funding round marks the largest ever for CellCure and the first commercial agreement for a Hadasit portfolio company. The event occurred on October 10, 2010.
Investment
CellCure Neurosciences Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 43 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
CellCure Neurosciences Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 513752394 |
| Crunchbase | cell-cure-neurosciences |
| Phone | +97225722000 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2022-12-20T00:00:00.000Z |
| Created | 2014-07-30T00:00:00.000Z |